Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
Go back to Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer| VERASTEM SHS (NASDAQ: VSTM) | Delayed: 8.20 +0.22 (2.76%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.98 | 52 Week High | $2.43 | |||
| Open | $7.91 | 52 Week Low | $1.05 | |||
| Day High | $8.21 | P/E | N/A | |||
| Day Low | $7.72 | EPS | $-1.79 | |||
| Volume | 2,301,510 | |||||
